ライフサイエンスコーパス: v

1 2) with a total electrolysis voltage of ~2.2 V.

2 ART in Fiebig I to 15.9 (7.6-29.2) in Fiebig V.

3 recipients, and those with fewer than four (vs.

4 scle diffusive O(2) conductance (6.6 +/- 0.8 vs.

5 e 0.84 and 0.86 for predicting N1 or higher (vs.

6 lightly less than in Europeans (ROC AUC 0.84 v 0.87, p < 0.0001).

7 igh-severity versus low-severity cases (0.98 vs 0.40 events/case, P < 0.001).

8 versus nonchylous fluids (mean, 6.2% +/- 4.3 vs 0.6% +/- 0.6; P < .001).

9 ation was higher with PN vs. Controls (12.5% vs. 0%, p = 0.024).

10 els, and lower nadir lymphocyte counts (0.09 vs. 0.4 x 10(3) /uL, P = .006).

11 [logMAR; Snellen equivalent, 20/200] in 2020 vs. 0.48 logMAR [Snellen equivalent, 20/60] in 2019; P =

12 ticipants for cpCD (0.32 [95% CI, 0.11-0.64] vs. 0.83 [95% CI, 0.69-0.93], respectively; P < 0.001).

13 itt score, 0 [interquartile range {IQR} 0-1] vs 1 [IQR 0-2] in patients with any positive BDG test; P

14 year was similar between groups (O:E = 0.65 vs 1.00, P = 0.11 and O:E = 0.79 vs 1.00, P = 0.15, resp

15 (O:E = 0.65 vs 1.00, P = 0.11 and O:E = 0.79 vs 1.00, P = 0.15, respectively).

16 aximum out-of-plane piezoresponse is 0.56 pm V(-1) , which is as strong as that observed in conventio

17 e, and for mobilities as low as 10(-3) cm(2) V(-1) s(-1) , [Formula: see text] Here, mu(w) is the wei

18 Reduced Ca(V) 1.3 activity might open new ways to understand sympto

19 y (basal) hair cells was also affected in Ca(V) 1.3(-/-) mice, but to a much lesser extent than apica

20 revealed a critical and selective role for K(v)1 channel inactivation in synaptic facilitation of exc

21 Changing activity of cardiac Ca(V)1.2 channels under basal conditions, during sympatheti

22 11)/ P2Y(11)-like receptors, AC5, PKA and Ca(V)1.2 into nanocomplexes at the plasma membrane of human

23 identified, in adult cardiac myocytes, a Na(V)1.5 subpopulation in close proximity to subjacent subs

24 Consequently, multiple Na(V)1.7-specific and Na(V)1.8-specific blockers have under

25 sequently, multiple Na(V)1.7-specific and Na(V)1.8-specific blockers have undergone clinical trials,

26 linical development, and the targeting of Na(V)1.9, although hampered by technical constraints, might

27 median: 3.4; interquartile range: 3.25-3.55) vs. 1.23 +/- 0.23 (median: 1.2; interquartile range: 1.0

28 and medical therapy was similar (1.3 vs. 2.1 vs. 1.6 years, respectively; P = 0.53).

29 vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18).

30 weeks (n = 523; 17% [300 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 t

31 occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute diffe

32 tly fewer AR and asthma prescriptions (59.7% vs 10.8%) than the control group, and the probability of

33 lower rate of neurologic complications (3/61 vs 10/53 for DHCA; p < 0.05) but not complications in ot

34 e high diversity 17 species communities (~30 vs. 10 species), and colonists collectively produced 10

35 60 pancreatoduodenectomies compared < 60 (4% vs. 10%, p = 0.046).

36 0(3) /uL, P = .019), C-reactive protein (198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL,

37 ly associated with Crohn's development (100% vs 11%; P < 0.01) compared with mild or nonspecific infl

38 months, women had a lower risk of MACE (9.5% vs. 11.2%; adjusted hazard ratio: 0.77; 95% confidence i

39 chromosomal changes were found in 0/20 blood vs. 11/20 aqueous samples along with shorter DNA fragmen

40 oup in the delayed assessment (89.45 [19.32] vs 110.10 [19.54]; p < 0.01).

41 interquartile range) pg/mL: 3285 (1697-6179) vs 1290 (758-3719); P < 0.001 and in patients developing

42 -fold greater response to NPC than ABEC (411 vs. 13 DEG).

43 965 fmol/punch (IQR:691, 1166) in pregnancy vs 1406 fmol/punch (IQR:1053, 1859) postpartum (p=0.006)

44 sample size was 49% (72 vs. 148) and 25% (36 vs. 142) of original sample size for MAIC of benralizuma

45 Effective sample size was 49% (72 vs. 148) and 25% (36 vs. 142) of original sample size fo

46 line was higher in Cit-B12 than placebo (33% vs 15%, p = 0.04).

47 .01), and experienced discrimination (29.0% vs 15.7%, P < .01) than whites (n = 121), blacks were on

48 l regimens (CTD, 13.2% vs 16.1%; CTDa, 10.7% vs 16.0%).

49 es of VTE for identical regimens (CTD, 13.2% vs 16.1%; CTDa, 10.7% vs 16.0%).

50 og scale (-11.5 in the zoledronic acid group vs -16.8 in the placebo group; between-group difference,

51 ms was higher in patients with COVID-19 (26% vs. 16.3% in patients without COVID-19, p=0.0197; relati

52 2 in NTS collected at enrollment (8/13 [62%] vs 17/17 [100%]; P = .02).

53 ificantly higher than in the HMS group (27.6 vs. 17.0 mmHg, P < 0.001).

54 vs 26.4%, P < .01), perceived racism (55.5% vs 18.2%, P < .01), and experienced discrimination (29.0

55 d corn with 75% stover removal (17.6 +/- 2.8 vs 18.8 +/- 3.0 g CO(2)e MJ(-1)), but were notably lower

56 lower in Group B than in Group A (128.68cm3 vs. 189.37cm3; p<0.05).

57 dian (interquartile range): 5196 (1823-9061) vs 1934 (831-5301); P = 0.005].

58 me (P > .05 for both 2010-2016 and 2003-2009 vs 1996-2002), and higher among black patients, those wi

59 2.5% v 3.9%) or genitourinary toxicity (2.9% v 2.9%).

60 16-18 years: aOR 0.75 [0.66-0.85]; p=0.0001 vs 2-5 years), and unknown HIV status of the mother (aOR

61 ital mortality (1.7% for uncemented fixation vs 2.0% for cemented fixation; HR, 0.94 [95% CI, 0.73-1.

62 FIT round compared to sigmoidoscopy at 1.4% vs 2.4% (OR, 0.57; 95% CI, 0.53-0.62) but higher after 3

63 higher after 3 cumulative FIT rounds at 2.7% vs 2.4% (OR, 1.14; 95% CI, 1.05-1.23).

64 ed with placebo (4.1 months [95% CI 3.3-4.8] vs 2.8 months [2.6-2.9]; HR 0.696 [95% CI 0.573-0.845];

65 e(2)/WSe(2), CoTe(2)/WSe(2), NbTe(2)/WSe(2), VS(2)/WSe(2), VSe(2)/MoS(2) and VSe(2)/WS(2).

66 sivity in the mucus obtained from adult pigs vs. 2-week old piglets showed better penetrability of th

67 198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphoc

68 , SAVR, and medical therapy was similar (1.3 vs. 2.1 vs. 1.6 years, respectively; P = 0.53).

69 laque were smaller (median thickness, 1.9 mm vs. 2.6 mm; LBD, 7.1 mm vs. 8.6 mm) and located closer t

70 nd located closer to foveola (median, 2.0 mm vs. 2.8 mm) than those treated with the 15-mm plaque (P

71 nd 90-day clinically relevant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p

72 red with episodes with no complications (28% vs 20%, respectively; risk difference, 7% [95% CI, 5.8%-

73 subsequent eye at presentation (mean, 20/62 vs. 20/149; P < 0.001) and postoperative month 6 (mean,

74 ; P = 0.03), but final VA was similar (20/36 vs. 20/37; P = 0.68).

75 .001) and postoperative month 6 (mean, 20/41 vs. 20/49; P = 0.03), but final VA was similar (20/36 vs

76 e and azithromycin in February to April 2020 vs 2019, and vs the top 10 most commonly prescribed drug

77 2%] of 66 patients in the intervention group vs 21 [32%] of 65 in the control group; adjusted odds ra

78 k (assistant 69.5% vs 41.8%; associate 17.6% vs 21.0%; full professor 13.0% vs 37.2%) were not signif

79 er baseline defect size (32.7 +/- 19.5 mm(2) vs 21.5 +/- 10.7 mm(2), p = 0.11).

80 e of local progression, 56% [range, 19%-91%] vs 22% [range, 12%-34%], respectively; P < .001) and con

81 patients received thromboprophylaxis (80.5% vs 22.3%) with lower rates of VTE for identical regimens

82 the southwestern study region (13.6 +/- 3.0 vs 22.5 +/- 3.1 g CO(2)e MJ(-1)).

83 ter operation: 20.0% for uncemented fixation vs 22.8% for cemented fixation; HR, 0.95 [95% CI, 0.90-1

84 vs 28%; p = 0.02) and less often asthma (8% vs 23%; p < 0.01).

85 zation in significantly more patients (72.7% vs 23.1% p = 0.04) despite overall larger baseline defec

86 genotype (3.8% vs. 4.4%) and C allele (20.4% vs. 23.9%) carriers were the lowest.

87 thout postoperative AF (incidence rate, 42.5 vs 25.0 per 1000 person-years; absolute RD at 5 years, 6

88 or care versus usual care: at 30 days (10.4% vs 26.3%; stabilized inverse probability of treatment we

89 ing higher levels of medical mistrust (40.0% vs 26.4%, P < .01), perceived racism (55.5% vs 18.2%, P

90 e of kidney failure (31.7% with intervention vs 27.3% with placebo; adjusted risk difference, 0.03; 9

91 d 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicotine replacement th

92 en had a primary diagnosis of pneumonia (41% vs 28%; p = 0.02) and less often asthma (8% vs 23%; p <

93 0.2; P = .58) or in 30-day mortality (34.7% vs 29.3%, respectively; hazard ratio, 1.3; 95% CI, 0.8-2

94 dence of late RT-related grade >= 3 GI (2.5% v 3.9%) or genitourinary toxicity (2.9% v 2.9%).

95 at mouse lymphatic muscle cells expressed Ca(v)3.1 and Ca(v)3.2 and produced functional T-type VGCC c

96 Concerning Ca(V)3.1, the compound did not alter the shape of the insta

97 hatic muscle cells expressed Ca(v)3.1 and Ca(v)3.2 and produced functional T-type VGCC currents when

98 res than the high diversity communities (~30 vs. 3 g/m(2) ).

99 (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69;

100 (median: 0.7; interquartile range: 0.4-1.15) vs. 3.63 +/- 0.29 (median: 3.7; interquartile range: 3.4

101 p with a low graft failure rate: 5% class 1, vs 30% class 2, vs 50% class 3 (P = .009).

102 7 months (95% confidence interval 38.5-75.5) vs 33 months (95% confidence interval 20.3-45.7), P = 0.

103 other career development award funding (55% vs 33%, P = 0.03) and more publications [median 70 (inte

104 ; 95% CI, 0.224-1.297) and at 60 days (16.7% vs 34.7%; stabilized inverse probability of treatment we

105 ver injury was lower in LT recipients (47.5% vs. 34.6%; P = 0.037).

106 erent countries (44-47% in Uganda and Zambia vs 36% in Nigeria).

107 Six of 143 died (4%) vs 362 of 2095 patients (17%, P < .001).

108 4% v 47%; P < .001), and overall period (64% v 37%; P < .001).

109 ence of posttraumatic stress disorder (52.4% vs 37.1%; p = 0.03).

110 sociate 17.6% vs 21.0%; full professor 13.0% vs 37.2%) were not significant after adjusting for caree

111 GG (63.1% vs. 56.7%) and CG genotypes (33.1% vs. 38.9%) and G allele of rs755622 (79.6% vs. 76.1%, re

112 in oxygen tension gradient (16 mm Hg [sd, 6] vs 39 mm Hg SD, 11]; p < 0.001) and in the relationship

113 CI, 79.0%-99.2%) with abbreviated breast MRI vs 39.1% (95% CI, 22.2%-59.2%) with DBT (P = .001) and s

114 MACE at 5 years compared with no PCI (31.5% vs 39.1%; hazard ratio, 0.77 [95% CI, 0.63-0.94]).

115 t DBT examination (6.1 per 1000 examinations vs 4.4-5.7 per 1000 examinations with at least one prior

116 < 0.01), lactate [1.1 mmol/L (IQR: 1.0-1.6) vs 4.6 mmol/L (IQR: 2.8-8.0), P < 0.01], and fraction of

117 LFT elevations occurred in 10% vs. 4% (p=0.28), and SCr elevations occurred in 20% vs.

118 6.1%, respectively), while CC genotype (3.8% vs. 4.4%) and C allele (20.4% vs. 23.9%) carriers were t

119 [median 70 (interquartile range, IQR 55-100) vs 40 (IQR 22-67), P = 0.03].

120 males at each academic rank (assistant 69.5% vs 41.8%; associate 17.6% vs 21.0%; full professor 13.0%

121 of symptoms (16/80 patients [19.5%] in 2020 vs. 41/106 patients [36.9%] in 2019; P = 0.005), and a g

122 raction of inspired oxygen [25% (IQR: 21-31) vs 42% (IQR: 30-80), P < 0.01] differed between survivor

123 rowth in all 3 sets of blood cultures (15.4% vs 45.1%; P = .005) and had less severe clinical present

124 or anxiety (55.2 vs. 50.0), depression (50.2 vs. 46.1), and somatization (70.3 vs. 61.8).

125 eight reductions 1 year after surgery (44.6% vs. 46.6%), 8 diabetes remitters had significant reducti

126 d (74% v 52%; P < .001), delayed period (74% v 47%; P < .001), and overall period (64% v 37%; P < .00

127 were 6.8 vs. 5.5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0.01), respectively.

128 mptoms less often than younger children (29% vs. 48%; p=0.01) or adolescents (29% vs. 60%; p<0.0001).

129 epithelialization within 3.56 +/- 1.78 weeks vs 5.87 +/- 2.20 weeks (p = 0.01) and achieved complete

130 enin activity and serum aldosterone were 6.8 vs. 5.5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0

131 primary PVR (11/82 patients [13.4%] in 2020 vs. 5/111 patients [4.5%] in 2019; P = 0.03).

132 ft failure rate: 5% class 1, vs 30% class 2, vs 50% class 3 (P = .009).

133 levated self-report scores for anxiety (55.2 vs. 50.0), depression (50.2 vs. 46.1), and somatization

134 he olanzapine group in the acute period (74% v 52%; P < .001), delayed period (74% v 47%; P < .001),

135 and ACS patients carried rs755622 GG (63.1% vs. 56.7%) and CG genotypes (33.1% vs. 38.9%) and G alle

136 ly than whites to initiate evaluation (49.6% vs 57.9%, P = .11).

137 ative American ancestry than controls (68.1% vs 58.6%; p = 5 x 10(-6)).

138 ter Universities Osteoarthritis Index (-37.5 vs -58.0, respectively; between-group difference, 20.5 [

139 ed (ejection fraction, day 2: 40.9% +/- 9.7% vs. 59.2% +/- 4.4%, P < 0.001).

140 changes in bone marrow lesion size (-33 mm2 vs -6 mm2; between-group difference, -27 mm2 [95% CI, -1

141 (p=0.28), and SCr elevations occurred in 20% vs. 6% (p=0.06) of patients with SRI versus those withou

142 ose with early/mild ILA at enrollment (63.3% vs. 6.1%; P < 0.0001).Conclusions: Rare and common envir

143 g (82.4% vs 70.6% in the training set, 66.7% vs 60.0% in the validation set, respectively).

144 : (30 min [interquartile range [IQR], 17-41] vs. 60 min [IQR, 45-60], P = 0.002).

145 en (29% vs. 48%; p=0.01) or adolescents (29% vs. 60%; p<0.0001).

146 sion (50.2 vs. 46.1), and somatization (70.3 vs. 61.8).

147 en were older (mean +/- SD age: 67.8 +/- 8.9 vs. 66.1 +/- 8.2 years; p < 0.001) and more likely to ha

148 eta-states (meta-state numbers, 75.8 +/- 7.9 vs 68.8 +/- 12.0, p = 0.043 FDR-corrected) and changes f

149 ad higher peak white blood cell counts (15.8 vs 7 x 10(3) /uL, P = .019), C-reactive protein (198 vs.

150 patients than the two-tiered testing (82.4% vs 70.6% in the training set, 66.7% vs 60.0% in the vali

151 to another (meta-state changes, 77.1 +/- 7.3 vs 71.2 +/- 11.0, p = 0.043 FDR-corrected) than beginner

152 l endoscopists were 88% vs 73% accuracy, 93% vs 72% sensitivity, and 83% vs 74% specificity.

153 n C-reactive protein [138 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), lactate [1.1 mmol/L

154 s those of the general endoscopists were 88% vs 73% accuracy, 93% vs 72% sensitivity, and 83% vs 74%

155 3% accuracy, 93% vs 72% sensitivity, and 83% vs 74% specificity.

156 % vs. 38.9%) and G allele of rs755622 (79.6% vs. 76.1%, respectively), while CC genotype (3.8% vs. 4.

157 ter 25 h shifts (predicted probability 99.4% vs 78.8%), whereas there was no relevant difference betw

158 ficant pathological regression (TRG1-2 = 44% vs 8%, P < 0.001) and a trend to tumor downstaging as co

159 trast, rates of intracerebral hemorrhage (6% vs 8%; p = 0.35) did not differ.

160 lacement therapy at 12 months (n = 257; 8.1% vs 8.2%).

161 mpared to those who remained negative (21.8% vs 8.5%, p=0.01; OR 3.0, 95%CI 1.31-6.87).

162 an thickness, 1.9 mm vs. 2.6 mm; LBD, 7.1 mm vs. 8.6 mm) and located closer to foveola (median, 2.0 m

163 e in the ICU at the time of diagnosis (21.0% vs. 8.6%, p = 0.024).

164 or those on DTG-based treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen

165 disease prevalence (93% accuracy for common vs 85% for rare diseases; P = .26).

166 or those on EFV-based treatment (60% [12/20] vs 86% [214/248], P = 0.002) and for those on DTG-based

167 3-year risk of subsequent admissions (72.6% vs 86.4%, p < 0.001) than those with NOM, with hazard ra

168 med than low cylinder power IOLs (<2 D) (27% vs 9%).

169 88; p < 0.001) and all-cause-mortality (7.6% vs. 9.7%; adjusted hazard ratio: 0.61; 95% confidence in

170 id and did not miss 7 consecutive doses (92% vs 93%, P = .897).

171 e beginning and end of 8 h day shifts (92.2% vs 97.3%).

172 specificity was 86.7% (95% CI, 84.8%-88.4%) vs 97.4% (95% CI, 96.5%-98.1%), respectively (P < .001).

173 To do this we screened the E90K GnRHR mutant vs. a library of 645,000 compounds using a cell-based ca

174 sis of DEG that were higher or lower in PVEC vs. ABEC identified "Nervous system development" and "Re

175 of definite NASH (ADH1B*2: OR, 0.80; P < .01 vs ADH1B*1: OR, 0.96; P = .036) and a reduced risk of an

176 of 4 or higher (ADH1B*2: OR, 0.83; P = .012 vs ADH1B*1: OR, 0.96; P = .048) (P < .01 for the differe

177 6.3% for ME after 5.5 h processing under 30 V and 15 V, respectively.

178 including the nepenthesin loop of plasmepsin V and a histidine in place of a catalytic aspartate in p

179 Concentrations of V and Cr(VI) co-exceeded health recommendations from the

180 In group I, CFT, IRT, ORT, foveal SCP-VD, and foveal DCP-VD were significantly greater than th

181 erformed a transcriptomics analysis of APOE4 vs. APOE3 expression in the entorhinal cortex (EC) and p

182 , there were 39% fewer flights in April 2020 vs April 2019.

183 motor, kinesin-1, and an actin motor, myosin-V, are essential for osk mRNA posterior localization.

184 ed dosing/treatment discontinuation in arm B vs arm C.

185 in situ generation of a uniquely reactive Bi(V) arylating agent from a bench-stable Bi(III) precursor

186 ected HLA-A*0201 positive symptomatic (SYMP) vs. asymptomatic (ASYMP) individuals and HLA-A*0201 tran

187 nanosheets array exhibits a voltage of 1.58 V at 30 mA cm(-2) as bifunctional electrode for water sp

188 e starvation-dependent increase in lysosomal V-ATPase activity without altering basal activity.

189 report two cryo-EM structures of the intact V-ATPase from bovine brain with all the subunits includi

190 ols, < 0.0001-0.03); improvement at month 18 vs baseline was higher in Cit-B12 than placebo (33% vs 1

191 peptide content and abrogated by anti-alpha(v)beta(3)) but not by A2780 (same as PEGylated particles

192 ling exponents of whole-plant metabolic rate vs body size numerically converge onto 1.0 after water c

193 Low Mg/Ca, and high U/Ca, Mo/Ca, and V/Ca potentially suggest a decreased abundance of "cente

194 the agreement between blood sources (venous vs capillary) and matrices (whole blood vs DBS).

195 nexpected stimulus-dependent diversity in Na(V) channel-mediated itch signalling.

196 o their mammalian counterparts, bacterial Na(V) channels possess a simpler, fourfold symmetric struct

197 Here, we use 490 Argentinian V. cholerae genome sequences to characterise the variati

198 resulted in a prolonged culturable state of V. cholerae in artificial sea water at 4 degrees C, wher

199 We demonstrate that cell shape in V. cholerae is regulated by the bacterial second messeng

200 virulence regulator, ToxR, was important for V. cholerae resistance to hydrogen peroxide.

201 stinal tract and which are substrates of the V. cholerae RND efflux systems.

202 protein necessary for curvature formation in V. cholerae.

203 on within, and between, epidemic and endemic V. cholerae.

204 ean false discovery rate Open Access = 0.241 vs. closed access = 0.225).

205 scertained that five coordinate amide iodine(V) complexes are unreactive toward redox reactions due t

206 injection time, injection method (pulsatile vs. continuous), or concomitant intravitreal melphalan u

207 ecreases in HBsAg to below 1 IU/mL (P < .001 vs control) and HBsAg seroconversion (P = .046 vs contro

208 control) and HBsAg seroconversion (P = .046 vs control).

209 vs naked antibody, and sacituzumab govitecan vs control-ADC, respectively).

210 ow any difference (DR: 0.03(-0.15,0.14)mg/dL vs. control: 0.09(-0.03,0.22)mg/dL;p = 0.797).

211 These simulations indicate that Motif V controls communication between the ATP-binding pocket

212 reased or not different in patients with IBD vs controls.

213 ostoperative constipation was higher with PN vs. Controls (12.5% vs. 0%, p = 0.024).

214 he analysis of 20 elements (Mg, P, S, K, Ca, V, Cr, Mn, Fe, Co, Cu, Zn, Se, Br, Rb, Sr, Mo, I, Cs, an

215 ses of patients with ulcerative colitis (UC) vs Crohn's disease (CD).

216 mechanisms that might contribute to aberrant V(D)J recombination and the development of lymphoid tumo

217 lele, with subsequent feedback inhibition of V(D)J recombination on the other allele.

218 Nuclear processes, such as V(D)J recombination, are orchestrated by the three-dimen

219 nous vs capillary) and matrices (whole blood vs DBS).

220 lites that differed between patients who did vs did not develop ACLF and patients who did vs did not

221 vs did not develop ACLF and patients who did vs did not die during hospitalization and within 30 days

222 input within the dendritic branch (proximal vs distal), (2) the strength of the input pattern (subth

223 enralizumab vs. mepolizumab and benralizumab vs. dupilumab, respectively.

224 Comparing outcomes of MMCR vs ELR in patients with severe ptosis, there was a stati

225 Molecular pathogenesis is preserved between V-EoE and L-EoE.

226 V-EoE was more likely to attain histologic remission via

227 lland (now Janssen Vaccines and Prevention B.V.), European Union's Horizon 2020 research and innovati

228 ecreased mitochondrial area, complex III and V expression increased in debanding compared with sham o

229 yes with repeatable glaucomatous SAP defects vs eyes with normal fields.

230 AL growth was analyzed relative to treated vs fellow eye, contact lens (CL) vs intraocular lens (IO

231 light-organ crypts, where the population of V. fischeri cells resides.

232 t for the polyfunctionality score in group 1 vs group 4b, p<0.01).

233 ters and their combinations to predict GGG 1 vs >1, using logistic regression with a nested leave-pai

234 200 (56%), patients with current CD4 351-500 vs >500 cells/muL had an aIRR of 1.22 (95% CI, .93-1.60)

235 ble analysis, endotracheal tube size (<= 7.5 vs >= 8.0) was significantly associated with patients ex

236 between patients on a GFD with new-onset CD vs healthy children were associated with nutrient and fo

237 of HCV+ nonviremic (HCV-NV) and viremic (HCV-V) hearts nationally and by UNOS region.

238 of the mother (aOR 0.81 [0.68-0.98], p=0.027 vs HIV-positive status).

239 tructures based on oxide perovskites and III-V, II-VI and transition metal dichalcogenide semiconduct

240 oplasmosis (14.0%) and blastomycosis (13.1%) vs. influenza (20.2%).

241 g/V initially tracks the current, increasing ~15-fold from

242 to treated vs fellow eye, contact lens (CL) vs intraocular lens (IOL), visual acuity (VA) outcome, a

243 ctives relative to nouns (e.g., "black lamp" vs. "lamp black") makes visual context information avail

244 Our results show that a low-voltage (<0.4 V) LEEFT has no obvious effect on the following ozonatio

245 ing ozonation, but a higher-voltage (0.6-1.2 V) LEEFT significantly enhances the ozone inactivation.

246 y reflecting desorption, while higher Cr and V levels were measured in near-neutral pH and oxic groun

247 The 25(OH)VD levels decreased from 26.3 +/- 10.7 ng/mL at baseline

248 , polymer nanopores), architecture (branched vs linear), functional groups (coordinating or ionic), s

249 elevant variables measured (including short- vs. long-term sexual strategy, temporal discounting, the

250 riginal sample size for MAIC of benralizumab vs. mepolizumab and benralizumab vs. dupilumab, respecti

251 cid site density and distribution (in micro- vs. mesopores), and catalytic activity suggest nearly in

252 y of EBV gH/gL and the EBV gH/gL-N(69)L/S(71)V mutant.

253 001, and p = 0.001 for sacituzumab govitecan vs naked antibody, and sacituzumab govitecan vs control-

254 and LZP inhibited responses to fearful faces vs. neutral faces within the centromedial amygdala (cmA)

255 V stiffness has not been compared between LF vs NF.

256 (26 [63%] of 41 patients with Zika infection vs nine [16%] of 55 with chikungunya infection; p<=0.000

257 ociation was attenuated (HR=1.03 [0.71-1.49] vs. NNRTIs) when accounting for 12-month weight.

258 9); P < 0.001 and in patients developing CPC vs no-CPC (area under the curve), median (interquartile

259 Just like the nature vs nurture debate, heterogeneity can arise from intrinsi

260 ective and diffusive O(2) delivery, and thus V O(2) , especially within fast-twitch oxidative skeleta

261 t systemic K(ATP) channel inhibition reduces V O(2) max and critical speed during treadmill running i

262 ctive dopant to modulate the oxygen vacancy (V(O) ) concentration and Ti(3+) formation, which markedl

263 erials whereby an increased concentration of V(O) sites correlates with a superior OER activity.

264 e concentration of surface oxygen vacancies (V(O)) in these materials whereby an increased concentrat

265 ta point to a novel "thiol-blocked" [(PDT)Mo(V)O(S(Cys))(thiolate)](-) structure, which is supported

266 A high mass activity (1.946 A mg(-1) at 0.45 V) of Pd(delta+)-OCNT is achieved.

267 nce (LR), (iv) disease free survival (DFS), (v) overall survival (OS).

268 orrelation between fractional plasma volume (V(p)), a parameter derived from DCE perfusion MRI, and h

269 in-down AHP, the former frequently induces a V-pattern esotropia requiring reoperation.

270 Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other tr

271 Z, S, or additional rare variants denoted as V(R).

272 adverse event rates associated with IV iron vs red cell transfusion and discuss using first-line IV

273 adults comparing Spanish regions using PCV13 vs regions using PPV23 vaccine was also analyzed for 201

274 Whether VD replacement during and after DAA therapy can improve

275 ME after 5.5 h processing under 30 V and 15 V, respectively.

276 w be considered as refractory to ruxolitinib vs ruxolitinib dependent.

277 at were activated, inactivated, or unchanged vs. RVD with no intervention.

278 icted to animals or to the presence of 4D-Na(v)s.

279 cid substitutions observed at positions T91A/V, S195D and M217T in relation to the RotaTeq vaccine we

280 tions between the stage of syphilis (primary vs secondary) and behavioral data collected by computer-

281 and 0.20 +/- 0.05, respectively, revealing a V-shaped SF/RH dependence.

282 ng effects that are unique (tissue-specific) vs. shared between tissues (tissue-shared).

283 for pointwise rates (medical therapy, 26.1% vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.42; P < 0.001).

284 This study implies a protective role for VD sufficiency throughout pregnancy, particularly in att

285 [(11)C]UCB-J V(T) was significantly lower in the frontal and anterior

286 mycin in February to April 2020 vs 2019, and vs the top 10 most commonly prescribed drugs in the same

287 Deltacreatinine post PCI in the DR group vs. the control group did not show any difference (DR: 0

288 tients and images) values for the CAD system vs those of the general endoscopists were 88% vs 73% acc

289 lsifier, hindered the polymorphic form IV-to-V transition.

290 n, calcium-binding proteins), pH regulation (V-type proton ATPase), and inorganic carbon regulation (

291 d components of the GCX under DF conditions, vs UF conditions, with undifferentiated levels of CTC-re

292 levels of CTC-recruiting E-selectin under DF vs UF conditions.

293 inegars, with a maximum addition fixed at 2% v/v by law.

294 Mean SCP VD values in 3 x 3-mm(2) scans were significantly higher

295 of 8.87 mA cm(-2) at low potential of -0.65 V versus RHE.

296 r frequency (TOF) up to 12500 h(-1) at -0.95 V versus the reversible hydrogen electrode (RHE), with a

297 Bulk electrolyses of 1 at -1.60 V vs SHE afford flavanone, 2'-hydroxychalcone, 2'-hydrox

298 CFT, IRT, ORT, foveal SCP-VD, and foveal DCP-VD were significantly greater than those in the other gr

299 ce rate ratios (IRRs) for black and Hispanic vs white populations in 6 cities in the United States (2

300 infections did not differ significantly with vs without ciprofloxacin prophylaxis.

301 om patients with sporadic CRC colonized with vs without CoPEC by quantitative reverse-transcription p